RBR-95yjmq进行中（未招募）3 期
Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of hydroxychloroquine and azithromycin versus placebo in the negative viral load of participants with flu syndrome caused by SARS-CoV2 and who have no indication for hospitalization - NA : NA
Hospital Santa Paula0 个研究点开始时间: 2020年4月29日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 65Y（—）
入选标准
- •Inclusion criteria
- •Age 18 and 65 years;
- •Flu syndrome for 48-120 hours characterized by the presence of at least two of the following: fever (may be absent), fatigue, cough (dry or productive), anorexia, malaise, muscle pain, sore throat, dyspnea, congestion nasal, anosmia, headache, diarrhea, nausea and vomiting. If the patient has pneumonia without signs of severity and without the need for supplemental oxygen, he will be eligible;
- •Infection with the SARS-CoV2 virus (COVID19), confirmed by a qualitative molecular test on nasopharyngeal and oropharyngeal swab samples;
- •Patients with no clinical indication for hospitalization;
- •Consent, voluntarily, to participate in the study by signing the Informed Consent Form (ICF).
排除标准
- •Exclusion criteria
- •History of allergy or hypersensitivity to hydroxychloroquine, azithromycin, or any other component of the study drugs;
- •Any other condition that contraindicates the use of hydroxychloroquine, including ocular retinopathy, G6PD deficiency, prolonged QTc;
- •History of any lung disease including, but not limited to: chronic obstructive pulmonary disease (COPD), asthma, structural lung diseases; pulmonary fibrosis;
- •Immunosuppressed patients, whether due to pre-existing diseases or through the use of immunosuppressive treatment;
- •Patients with any malignancy;
- •History of any neurological event, including seizure, stroke, TIA and others;
- •History of cardiopathies or cardiovascular diseases, including severe arterial hypertension (defined by systolic pressure 160mmHg and / or diastolic pressure 100mgHg), atrial fibrillation, AMI, VTE, cardiac arrhythmias and others;
- •Prolonged Qt interval (Qtc greater than 480ms), evidenced by the ECG at the time of inclusion in the study;
- •Altered values ??of creatine phosphokinase (CPK): 5x above LSN
- •Altered values ??for lactic dehydrogenase (LDH): greater than 1000U / L
- •Insulin dependent diabetic patients;
- •Patients with renal failure defined by creatinine clearance less than 50mL / min calculated by the Cockcroft-Gault formula
- •Patients with significant hematological changes, defined by: anemia (hemoglobin less than 10g / dL), thrombocytopenia (platelets less than 100,000 / mm3), or leukopenia (leukocytes less than 2,000 / mm3)
- •Patients with TGO or TGP values ??2.5x above ULN or altered prothrombin time (INR above 1.5);
- •Patients with lower D-dimer3g / L at the time of inclusion in the study;
- •Patients already using hydroxychloroquine and its derivatives and / or azithromycin at the time of inclusion in the study;
- •Patients using antiretrovirals;
- •Patients participating in any clinical study, in the last 6 months until the moment of inclusion in the study;
- •Pregnant or breastfeeding women. For all women of childbearing potential who are able to become pregnant, a quantitative test will be performed at the screening visit to evaluate hCG in a blood sample to rule out pregnancy.
研究者
相似试验
已完成
2 期
Randomized, double-blind, placebo-controlled clinical trial of sublingual immunotherapy in natural rubber latex allergic patientsatex allergyInflammatory and Immune System - AllergiesLatex allergyACTRN12611000543987Allergy Service. Hospital Santiago Apostol28
进行中（未招募）
1 期
The aim of the study is to analyze whether the administration of a vaccine against COVID19 infection can reduce the symptoms of long COVID.nlike what happens with other respiratory viruses, in a significant proportion of patients who have suffered from the disease, general and multi-organ symptoms may persist for months, which has been called long COVIDEUCTR2021-003331-28-ESFelix Gutierrez Rodero776
进行中（未招募）
1 期
Evaluation of the Immodin effectiveness on the immune system of healthy volunteersEUCTR2012-001709-26-CZSevapharma,a.s.
进行中（未招募）
1 期
Clinical trial to evaluate the effect of Raltegravir intensification (1.200 mg QD) on the gut microbiota of chronically HIV-1 infected subject over timeHIV-1MedDRA version: 19.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-002722-36-ESFUNDACIÓ LLUITA CONTRA LA SIDA
招募中
4 期
Randomized, double-blind, placebo-controlled clinical trial of Jingu Zhitong Ningjiao in treatment of knee osteoarthritis with kidney deficiency and blood stasisknee osteoarthritisITMCTR2024000175The First Affiliated Hospital of Tianjin University of Chinese Medicine, Tianjin, China